Skip to main content
. Author manuscript; available in PMC: 2020 Mar 16.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2019 Jan 30;28(5):935–942. doi: 10.1158/1055-9965.EPI-18-0356

Table 2.

Association between platelet count and risk of lung cancer using multiple IV analysis

SNP Overall NSCLC AC SqCC SCLC
OR (95%CI) P OR (95%CI) P OR (95%CI) P OR (95%CI) P
IVW 1.62 (1.15, 2.27) 0.005 1.51 (0.92, 2.48) 0.11 1.59 (0.86, 2.92) 0.14 3.00 (1.27, 7.06) 0.01
Penalized IVW 1.62 (1.15, 2.27) 0.005 1.51 (0.92, 2.48) 0.11 1.59 (0.86, 2.92) 0.14 3.00 (1.27, 7.06) 0.01
Robust IVW 1.63 (1.26, 2.11) <0.001 1.51 (0.90, 2.53) 0.12 1.54 (0.93, 2.56) 0.09 3.30 (1.52, 7.15) 0.003
MR-Egger 3.25 (1.16, 9.11) 0.03 6.06 (1.45, 25.27) 0.01 1.75 (0.22, 13.84) 0.59 3.29 (0.24, 45.11) 0.37
Penalized MR-Egger 3.25 (1.16, 9.11) 0.03 6.06 (1.45, 25.27) 0.01 1.75 (0.22, 13.84) 0.59 3.29 (0.24, 45.11) 0.37
Robust MR-Egger 3.23 (1.80, 5.78) <0.001 5.88 (2.74, 12.61) <0.001 1.70 (0.48, 6.08) 0.41 3.56 (1.25, 10.14) 0.02

OR, odds ratio of platelet count (PLT) on lung cancer risk per 100×109/L increment of PLT; NSCLC, non-small cell lung cancer; AC, adenocarcinoma; SqCC, squamous cell carcinoma; SCLC, small-cell carcinoma; IVW, inverse-variance weighted.